New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials
NCT ID NCT07653685
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TQB2930, which targets the HER2 protein on cancer cells, combined with standard chemotherapy and possibly another drug (bevacizumab). The goal is to find the safest and most effective dose and see if it shrinks tumors in people with advanced colorectal cancer that cannot be removed by surgery. About 71 participants aged 18-75 with HER2-positive disease will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQB2930 injection (a drug targeting HER2 protein on cancer cells) combined with chemotherapy (oxaliplatin, capecitabine) and possibly bevacizumab
- What this could lead to
- If successful, this could lead to a new treatment option for people with HER2-positive advanced colorectal cancer that has not responded to other therapies.
- What could go wrong
- This is an early-phase trial with only 71 participants, so results may not apply to everyone. The drug combination may cause side effects or not shrink tumors as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gansu Provincial Tumor Hospital
Lanzhou, Gansu, 730050, China
-
Guangxi Zhuang Autonomous Region Cancer Hospital
Nanning, Guangxi, 530000, China
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangsu Provincial Cancer Hospital
Nanjing, Jiangsu, 210000, China
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
-
Jingzhou First People's Hospital
Jingzhou, Hubei, 434099, China
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110000, China
-
Lishui Municipal Central Hospital
Lishui, Zhejiang, 323000, China
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
-
The Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, 563000, China
-
The First Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710000, China
-
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, Shaanxi, 710000, China
-
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710000, China
-
The Third People's Hospital of Zhengzhou
Zhengzhou, Henan, 450000, China
-
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, 450000, China
-
The first hospital of Jilin University
Changchun, Jilin, 130021, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
-
Tianjin Union Medical Center
Tianjin, Tianjin Municipality, 300121, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang, 830054, China
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?